Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zavicefta for hospital-acquired pneumonia (including ventilator-associated pneumonia) in Chinese adults
CTR20210164Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2021
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ceftazidime + avibactam in hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), sponsored by AstraZeneca. Started Feb 2021; status: completed.
02
Drugs
ceftazidime + avibactam
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on CTR20210164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210164.